Cargando…

“Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use the...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpern, Bruno, Mancini, Marcio C., van de Sande-Lee, Simone, Miranda, Paulo Augusto Carvalho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665066/
https://www.ncbi.nlm.nih.gov/pubmed/37585688
http://dx.doi.org/10.20945/2359-4292-2023-0174
_version_ 1785138748642557952
author Halpern, Bruno
Mancini, Marcio C.
van de Sande-Lee, Simone
Miranda, Paulo Augusto Carvalho
author_facet Halpern, Bruno
Mancini, Marcio C.
van de Sande-Lee, Simone
Miranda, Paulo Augusto Carvalho
author_sort Halpern, Bruno
collection PubMed
description Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as “medications to treat obesity” or “anti-obesity medications” conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care.
format Online
Article
Text
id pubmed-10665066
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-106650662023-08-16 “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) Halpern, Bruno Mancini, Marcio C. van de Sande-Lee, Simone Miranda, Paulo Augusto Carvalho Arch Endocrinol Metab Consensus Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as “medications to treat obesity” or “anti-obesity medications” conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care. Sociedade Brasileira de Endocrinologia e Metabologia 2023-08-16 /pmc/articles/PMC10665066/ /pubmed/37585688 http://dx.doi.org/10.20945/2359-4292-2023-0174 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Consensus
Halpern, Bruno
Mancini, Marcio C.
van de Sande-Lee, Simone
Miranda, Paulo Augusto Carvalho
“Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_full “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_fullStr “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_full_unstemmed “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_short “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_sort “anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the brazilian association for the study of obesity and metabolic syndrome (abeso) and the brazilian society of endocrinology and metabolism (sbem)
topic Consensus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665066/
https://www.ncbi.nlm.nih.gov/pubmed/37585688
http://dx.doi.org/10.20945/2359-4292-2023-0174
work_keys_str_mv AT halpernbruno antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem
AT mancinimarcioc antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem
AT vandesandeleesimone antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem
AT mirandapauloaugustocarvalho antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem